DOI QR코드

DOI QR Code

Combination Doxorubicin and Interferon-α Therapy Stimulates Immunogenicity of Murine Pancreatic Cancer Panc02 Cells via Up-regulation of NKG2D ligands and MHC Class I

  • Wang, Wen-Jia (Institute of Pharmacy, Tumor Hospital of Jilin Province) ;
  • Qin, Si-Hao (Institute of Medicine, Tumor Hospital of Jilin Province) ;
  • Zhang, Ji-Wei (Department of Neurosurgery, Tumor Hospital of Jilin Province) ;
  • Jiang, Yue-Yao (Institute of Pharmacy, Tumor Hospital of Jilin Province) ;
  • Zhang, Jin-Nan (Department of Neurosurgery, China-Japan Friendship Hospital) ;
  • Zhao, Lei (Institute of Frontier Medical Science, Jilin University)
  • 발행 : 2014.12.18

초록

Background: Pancreatic adenocarcinoma is a malignant gastrointestinal cancer with significant morbidity and mortality. Despite severe side effects of chemotherapy, the use of immunotherapy combined with chemotherapy has emerged as a common clinical treatment. In this study, we investigated the efficacy of the combined doxorubicin and interferon-${\alpha}$ (IFN-${\alpha}$) therapy on murine pancreatic cancer Panc02 cells in vitro and in vivo and underlying mechanisms. Materials and Methods: A Panc02-bearing mouse model was established to determine whether doxorubicin and interferon-${\alpha}$ (IFN-${\alpha}$) could effectively inhibit tumor growth in vivo. Cytotoxicity of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) was evaluated using a standard LDH release assay. To evaluate the relevance of NK cells and CD8 T cells to the combination therapy-mediated anti-tumor effects, they were depleted in tumor-bearing mice by injecting anti-asialo-GM-1 antibodies or anti-CD8 antibodies, respectively. Finally, the influence of doxorubicin+interferon-${\alpha}$ (IFN-${\alpha}$) on the ligands of NK and T cells was assessed by flow cytometry. Results: The combination therapy group demonstrated a significant inhibition of growth of Panc02 in vivo, resulting from activated cytotoxicity of NK cells and CTLs. Depleting CD8 T cells or NK cells reduced the anticancer effects mediated by immunochemotherapy. Furthermore, the doxorubicin+IFN-a treatment increased the expression of major histocompatibility complex class I (MHC I) and NKG2D ligands on Panc02 cells, suggesting that the combined therapy may be a potential strategy for enhancing immunogenicity of tumors. All these data indicate that the combination therapy using doxorubicin and interferon-${\alpha}$ (IFN-${\alpha}$) may be a potential strategy for treating pancreatic adenocarcinoma.

키워드

참고문헌

  1. Bandyopadhyay A, Wang L, Agyin J, et al (2010). Doxorubicin in combination with a small TGF-$\beta$ inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One, 5, 10365. https://doi.org/10.1371/journal.pone.0010365
  2. Casares N, Pequignot MO, Tesniere A, et al (2005). Caspasedependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med, 202, 1691-701. https://doi.org/10.1084/jem.20050915
  3. Carayannopoulos LN, Naidenko OV, Fremont DH, Yokoyama WM (2002). Cutting edge: murine UL16-binding proteinlike transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol, 169, 4079-83. https://doi.org/10.4049/jimmunol.169.8.4079
  4. Gabrilovich DI (2007). Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. Lancet Oncol, 8, 2-3. https://doi.org/10.1016/S1470-2045(06)70985-8
  5. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH (2000). Ligands for the murine NKG2D receptor expression by tumor cells and activation of NK cells and macrophages. Nat Immunol, 1, 119-26. https://doi.org/10.1038/77793
  6. Gasser S, Orsulic S, Brown EJ, Raulet DH (2005). The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature, 436, 1186-90. https://doi.org/10.1038/nature03884
  7. Gromme M, Neefjes J (2002). Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. Mol Immunol, 39, 181-202. https://doi.org/10.1016/S0161-5890(02)00101-3
  8. Gutterman JU (1994). Cytokine therapeutics lessons from interferon alpha. P Natl Acad Sci USA, 91, 1198-205. https://doi.org/10.1073/pnas.91.4.1198
  9. Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. Ca-Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
  10. Karre K (2002). NK cells, MHC class I molecules and the missing self. Scand J Immunol, 55, 221-8. https://doi.org/10.1046/j.1365-3083.2002.01053.x
  11. Ke M, Wang H, Zhang M, et al (2014). The anti-lung cancer activity of SEP is mediated by the activation and cytotoxicity of NK cells via TLR2/4 in vivo. Biochem Pharmacol, 89, 119-30. https://doi.org/10.1016/j.bcp.2014.02.024
  12. Khallouf H, Marten A, Serba S, et al (2012). 5-Fluorouracil and interferon-$\alpha$ immunochemotheraoy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligangs and MHC class I. J Immunother, 35, 245-53. https://doi.org/10.1097/CJI.0b013e31824b3a76
  13. Ma JH, Patrut E, Schmidt J, et al (2005). Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma. World J Gastroenterol, 11, 1521-8. https://doi.org/10.3748/wjg.v11.i10.1521
  14. Ma XL, Li YY, Zhang J, et al (2014). Prognostic role of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. Asian Pac J Cancer Prev, 15, 6015-20. https://doi.org/10.7314/APJCP.2014.15.15.6015
  15. Marrack P, Kappler J, Mitchell T (1999). Type I interferons keep activated T cells alive. J Exp Med, 189, 521-30. https://doi.org/10.1084/jem.189.3.521
  16. Mattarollo SR, Loi S, Duret H, et al (2011). Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res, 71, 4809-20. https://doi.org/10.1158/0008-5472.CAN-11-0753
  17. Neoptolemos JP, Stocken DD, Friess H, et al (2004). A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. New Engl J Med, 350, 1200-10. https://doi.org/10.1056/NEJMoa032295
  18. Nugroho AE, Hermawan A, Nastiti K, Suven Elisa P, et al (2012). Immunomodulatory effects of hexane insoluble fraction of Ficus septica Burm. F. in doxorubicin-treated rats. Asian Pac J Cancer Prev, 13, 5785-90. https://doi.org/10.7314/APJCP.2012.13.11.5785
  19. Pende D, Rivera P, Marcenaro S, et al (2002). Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes:analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res, 62, 6178-86.
  20. Pfeffer LM, Dinarello CA, Herberman RB, et al (1998). Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res, 58, 2489-99.
  21. Raulet DH (2003). Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol, 3, 781-90. https://doi.org/10.1038/nri1199
  22. Salih HR, Antropius H, Gieseke F, et al (2003). Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood, 102, 1389-96. https://doi.org/10.1182/blood-2003-01-0019
  23. Sandel MH, Speetjens FM, Menon AG, et al (2005). Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol Immunol, 42, 541-6. https://doi.org/10.1016/j.molimm.2004.07.039
  24. Savage P, Costelna D, Moore J, Gore ME (1997). A phase II study of continuous infusional 5-Fluorouracil and subcutaneous Interleukin-2 (IL-2) in metastatic renal cancer. Eur J Cancer, 33, 1149-51. https://doi.org/10.1016/S0959-8049(96)00515-1
  25. Sener SF, Fremgen A, Menck HR, Winchester DP (1999). Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surgeons, 18, 1-7.
  26. Siddle, HV, Kreiss, A, Tovar C, et al (2013). Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer. P Natl Acad Sca USA, 110, 5103-8. https://doi.org/10.1073/pnas.1219920110
  27. Soriani A, Zingoni A, Cerboni C, et al (2009). ATM-ATRdependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood, 113, 3503-11. https://doi.org/10.1182/blood-2008-08-173914
  28. Stojanovic A, Cerwenka A (2011). Natural killer cells and solid tumors. J Innate Immun, 3, 355-64. https://doi.org/10.1159/000325465
  29. Tacar O, Sriamornsak P, Dass CR (2013). Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmaco, 65, 157-70. https://doi.org/10.1111/j.2042-7158.2012.01567.x
  30. Uram JN, Le DT (2013). Current advances in immunotherapy for pancreatic cancer. Curr Prob Cancer, 37, 273-9. https://doi.org/10.1016/j.currproblcancer.2013.10.004
  31. Zhao L, Wang WJ, Zhang JN, Zhang XY (2014). 5-Fluorouracil and interleukin-2 immunochemotherapy enhances immunogenicity of non-small cell lung cancer A549 cells through upregulation of NKG2D ligands. Asian Pac J Cancer Prev, 15, 4039-44. https://doi.org/10.7314/APJCP.2014.15.9.4039

피인용 문헌

  1. Effect of Cisplatin on the Frequency and Immuno-inhibitory Function of Myeloid-derived Suppressor Cells in A375 Melanoma Model vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4329
  2. Expression Pattern and Prognostic Significance of Claudin 1, 4 and 7 in Pancreatic Cancer vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4387
  3. Increased UGT1A3 and UGT1A7 Expression is Associated with Pancreatic Cancer vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1651
  4. Increase of Tumor Infiltrating γδ T-cells in Pancreatic Ductal Adenocarcinoma Through Remodeling of the Extracellular Matrix by a Hyaluronan Synthesis Suppressor, 4-Methylumbelliferone vol.48, pp.2, 2019, https://doi.org/10.1097/MPA.0000000000001211